Guillain–Barré Syndrome as a Neurological Complication of COVID-19 Infection: A Case Series and Review of the Literature
International Clinical Neuroscience Journal,
Vol. 7 No. 3 (2020),
21 June 2020
,
Page 156-161
Abstract
Background: The novel coronavirus (COVID-19) is a global pandemic. Although the main clinical manifestations of the COVID-19 infection has confined to the respiratory system, there is some evidence suggesting the neuro-invasive potential of the COVID-19. There are limited reports of Guillain–Barré syndrome (GBS) as a peripheral nervous system complication of COVID-19 infection.
Methods and results: We described four patients with COVID-19 infection who developed acute polyneuropathy with a final diagnosis of Guillain–Barré syndrome.
Conclusion: COVID-19 may have the potential to invade the peripheral nervous system. GBS, as one of the critical neurological complications of COVID-19, could be considered as a post-infectious event.
- Novel corona-virus
- COVID -19
- neurological complication
- Guillain–Barré syndrome
- GBS
How to Cite
References
Wang C, Horby P, Hayden F, Gao G. A novel coronavirus outbreak of global health concern. The Lancet. 2020;395.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
Sheng J, Shao A. The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event. 1920.
Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A Literature Review. Journal of Clinical Neuroscience. 2020.
Sejvar J, Kohl K, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599-612.
Paybast S, Emami A, Koosha M, Baghalha F. Novel Coronavirus Disease (COVID-19) and Central Nervous System Complications: What Neurologist Need to Know. Acta Neurologica Taiwanica. 2020;29(1):24-31.
Dhadke SV, Dhadke VN, Bangar SS, Korade MB. Clinical profile of Guillain Barre syndrome. J Assoc Physicians India. 2013;61(3):168-72.
Nyati KK, Nyati R. Role of Campylobacter jejuni infection in the pathogenesis of Guillain-Barré syndrome: an update. BioMed research international. 2013;2013.
Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet Neurology. 2020;19(5):383-4.
Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. Journal of Clinical Neuroscience. 2020.
Virani A, Rabold E, Hanson T, Haag A, Elrufay R, Cheema T, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection. IDCases. 2020:e00771.
Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain–Barré syndrome associated with SARS-CoV-2. New England Journal of Medicine. 2020.
McGonagle D, Sharif K, O'Regan A, Bridgewood C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmunity reviews. 2020:102537.
- Abstract Viewed: 663 times
- PDF Downloaded: 767 times